Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Plugin JSON Content Importer Pro not running: Check Licence! Check that a Licence is active for https://freeline.life
You might also like
Freeline Doses Second Patient of Phase 1/2 MARVEL-1 Clinical Trial for Fabry Disease
Freeline Therapeutics to Host Full Year 2022 Financial Results Call
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease
Freeline Reports January 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Freeline Reports October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Get in touch

+44 (0)1438 906870
contact@freeline.life

Follow us on our social channels